論文

査読有り 国際誌
2020年4月13日

Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice.

International journal of cardiology
  • Kenjiro Tsuruoka
  • ,
  • Shigeo Wakabayashi
  • ,
  • Hirofumi Morihara
  • ,
  • Ninso Matsunaga
  • ,
  • Yasuhito Fujisaka
  • ,
  • Isao Goto
  • ,
  • Akihisa Imagawa
  • ,
  • Michio Asahi

記述言語
英語
掲載種別
DOI
10.1016/j.ijcard.2020.04.033

BACKGROUND: Although immune checkpoint inhibitors (ICIs) have made an immense breakthrough in cancer therapeutics, they can exert unique, immune-related adverse events. Among them, myocarditis is less frequent, but it is serious and often follows a lethal course. METHODS: To examine the changes in cardiac autoimmunity after ICI administration, we developed a mouse experimental autoimmune myocarditis (EAM) model via intraperitoneal administration of murine α-cardiac myosin heavy chain (MyHC-α) fragment. Thereafter, the mouse anti-PD-1 antibody (mPD1ab) was administered at two time points, subsequent to and concurrent with MyHC-α fragment administration. RESULTS: Severe EAM developed in 3 weeks; wide inflammatory lesions were observed in the cardiac sections. Furthermore, inflammatory/fibrotic genes, such as interleukin 1β, interleukin 6, and collagen 1, were upregulated, although the cardiac function was not significantly affected. The subsequent administration of mPD1ab at 2 weeks post administration of the first MyHC-α fragment exacerbated EAM, whereas the administration of mPD1ab concurrent with MyHC-α fragment administration did not exacerbate EAM. The subsequent administration of mPD1ab significantly increased the infiltration of cluster of differentiation (CD)4- and F4/80-positive cells, whereas the concurrent administration of mPD1ab significantly decreased the infiltration of CD4-positive cells, indicating that the concurrent and subsequent administration of mPD1ab had opposite effects on immune/inflammatory cell infiltration. CONCLUSIONS: These data suggest that the appearance of ICI-induced autoimmune myocarditis might be related to autoimmune system activity before ICI administration. Although ICIs do not adversely affect patients with normal immune systems, we propose that ICI administration should be avoided in patients with autoimmune disorders.

リンク情報
DOI
https://doi.org/10.1016/j.ijcard.2020.04.033
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32402518
ID情報
  • DOI : 10.1016/j.ijcard.2020.04.033
  • PubMed ID : 32402518

エクスポート
BibTeX RIS